Third generation IVF : PGT-A

In combination with the second-generation IVF technology and Preimplantation

Genetic Testing for Aneuploidy (PGT-A), the third generation

IVF technology focuses on chromosome analysis before embryo implantation. When the cultured embryo developed to the 5th-6th day (blastocyst stage), 5-10 cells of the trophectoderm on the periphery of the embryo are taken out by embryo biopsy, and a molecular diagnostic method is used to check whether there are a full set of 46 chromosomes. After confirming that there is no abnormality, the healthy embryo will be implanted. Our PGT-A adopts advanced next generation sequencing (NGS) technology, which can provide fast, high-accuracy, and high-resolution chromosome analysis.

Application

Couples with the following conditions are recommended to take PGT-A to increase pregnancy rate.

• Women over 38 years old

• Those who have recurrent miscarriage

• Those who have failed embryo implantation multiple times

• Those who try to avoid fetal chromosomal abnormalities

• Those who have failed IVF multiple times

• Those with abnormal number of chromosomes or chromosomal trans locations in their family history